Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Piperazine-substituted chalcones: a new class of MAO-B, AChE, and BACE-1 inhibitors for the treatment of neurological disorders
Bijo Mathew, Jong‐Min Oh, Roua S. Baty, et al.
Environmental Science and Pollution Research (2021) Vol. 28, Iss. 29, pp. 38855-38866
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Monoamine oxidase inhibitors: A concise review with special emphasis on structure activity relationship studies
Bhawna Verma, Ashwani Kumar, Meenakshi Bhatia, et al.
European Journal of Medicinal Chemistry (2022) Vol. 242, pp. 114655-114655
Closed Access | Times Cited: 37
Targeting of neuroinflammation by glibenclamide in Covid-19: old weapon from arsenal
Gaber El‐Saber Batiha, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Inflammopharmacology (2022) Vol. 31, Iss. 1, pp. 1-7
Open Access | Times Cited: 37
Development of Isopropyl-Tailed Chalcones as a New Class of Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disorder
Sunil Kumar, Jong‐Min Oh, Mohamed A. Abdelgawad, et al.
ACS Omega (2023) Vol. 8, Iss. 7, pp. 6908-6917
Open Access | Times Cited: 26
Development of bromo- and fluoro-based α, β-unsaturated ketones as highly potent MAO-B inhibitors for the treatment of Parkinson's disease
Mohamed A. Abdelgawad, Jong‐Min Oh, Della Grace Thomas Parambi, et al.
Journal of Molecular Structure (2022) Vol. 1266, pp. 133545-133545
Closed Access | Times Cited: 33
Chalcone Derivatives with a High Potential as Multifunctional Antioxidant Neuroprotectors
Adriana Pérez‐González, Romina Castañeda‐Arriaga, Eduardo Gabriel Guzmán‐López, et al.
ACS Omega (2022) Vol. 7, Iss. 43, pp. 38254-38268
Open Access | Times Cited: 33
Introduction of benzyloxy pharmacophore into aryl/heteroaryl chalcone motifs as a new class of monoamine oxidase B inhibitors
Sachithra Thazhathuveedu Sudevan, Jong‐Min Oh, Mohamed A. Abdelgawad, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 27
The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer’s disease
Mariana G. Fronza, Diego Alves, Domenico Praticò, et al.
Ageing Research Reviews (2023) Vol. 90, pp. 102033-102033
Closed Access | Times Cited: 20
Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer’s disease
Da-Jiang Zou, Renzheng Liu, Yangjing Lv, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 18
Light-mediated Activation/Deactivation Control and in vitro ADMETox Profiling of a Donepezil-like Dual AChE/MAO-B Inhibitor
Federica Poggialini, Paolo Governa, Chiara Vagaggini, et al.
European Journal of Pharmaceutical Sciences (2025), pp. 107066-107066
Open Access
Halogenated Coumarin–Chalcones as Multifunctional Monoamine Oxidase-B and Butyrylcholinesterase Inhibitors
Nisha Abdul Rehuman, Jong‐Min Oh, Lekshmi R. Nath, et al.
ACS Omega (2021) Vol. 6, Iss. 42, pp. 28182-28193
Open Access | Times Cited: 37
Dual-Target Inhibitors Based on Acetylcholinesterase: Novel Agents for Alzheimer's Disease
Xingyi Zhao, Qiaoguan Hu, Xiaoqian Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116810-116810
Closed Access | Times Cited: 4
Trimethoxylated Halogenated Chalcones as Dual Inhibitors of MAO-B and BACE-1 for the Treatment of Neurodegenerative Disorders
Vishal Payyalot Vishal, Jong‐Min Oh, Ahmed Khames, et al.
Pharmaceutics (2021) Vol. 13, Iss. 6, pp. 850-850
Open Access | Times Cited: 29
Chalcones as Potential Ligands for the Treatment of Parkinson’s Disease
Ewelina Królicka, Katarzyna Kieć‐Kononowicz, Dorota Łażewska
Pharmaceuticals (2022) Vol. 15, Iss. 7, pp. 847-847
Open Access | Times Cited: 20
Identification of New N-methyl-piperazine Chalcones as Dual MAO-B/AChE Inhibitors
Ashraf K. El‐Damasy, Jong‐Eun Park, Hyun Ji Kim, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 1, pp. 83-83
Open Access | Times Cited: 11
A structural approach to investigate halogen substituted MAO-B inhibitors using QSAR modeling, molecular dynamics, and conceptual DFT analysis
Naseer Maliyakkal, Iqrar Ahmad, Sunil Kumar, et al.
Journal of Saudi Chemical Society (2023) Vol. 27, Iss. 4, pp. 101675-101675
Open Access | Times Cited: 11
Structural Modifications on Chalcone Framework for Developing New Class of Cholinesterase Inhibitors
Ginson George, Vishal Payyalot Koyiparambath, Sukumaran Sunitha, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3121-3121
Open Access | Times Cited: 15
Halogenated class of oximes as a new class of monoamine oxidase-B inhibitors for the treatment of Parkinson’s disease: Synthesis, biochemistry, and molecular dynamics study
Della Grace Thomas Parambi, Jong‐Min Oh, Sunil Kumar, et al.
Computational Biology and Chemistry (2023) Vol. 105, pp. 107899-107899
Closed Access | Times Cited: 7
Investigation on Novel E/Z 2-Benzylideneindan-1-One-Based Photoswitches with AChE and MAO-B Dual Inhibitory Activity
Marco Paolino, Modesto de Candia, Rosa Purgatorio, et al.
Molecules (2023) Vol. 28, Iss. 15, pp. 5857-5857
Open Access | Times Cited: 7
Current Approaches and Tools Used in Drug Development against Parkinson’s Disease
Oliwia Koszła, Piotr Stępnicki, Agata Zięba, et al.
Biomolecules (2021) Vol. 11, Iss. 6, pp. 897-897
Open Access | Times Cited: 14
Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones
Ashutosh Kumar Singh, Seong‐Min Kim, Jong‐Min Oh, et al.
Chemical Biology & Drug Design (2023) Vol. 102, Iss. 2, pp. 271-284
Open Access | Times Cited: 5
Ameliorative effect of ethoxylated chalcone-based MAO-B inhibitor on behavioural predictors of haloperidol-induced Parkinsonism in mice: evidence of its antioxidative role against Parkinson’s diseases
Naseer Maliyakkal, Uzma Saleem, Fareeha Anwar, et al.
Environmental Science and Pollution Research (2021) Vol. 29, Iss. 5, pp. 7271-7282
Closed Access | Times Cited: 13
Chalcones with N‐Methylpiperazine Moiety: Synthesis, Monoamine Oxidase Inhibition, Neuroprotective Effect and Computer Simulation Study
Jayalakshmi Jayan, Daniela Trisciuzzi, Feba Benny, et al.
ChemistrySelect (2024) Vol. 9, Iss. 14
Closed Access | Times Cited: 1
A Comprehensive Review of the Docking Studies of Chalcone for the Development of Selective MAO-B Inhibitors
Athulya Krishna, Sunil Kumar, Sachithra Thazhathuveedu Sudevan, et al.
CNS & Neurological Disorders - Drug Targets (2023) Vol. 23, Iss. 6, pp. 697-714
Closed Access | Times Cited: 4
Design and synthesis of novel chalcone derivatives and evaluation of their inhibitory activities against acetylcholinesterase
İlçim Ceyhun, Şevval Karaca, Derya Osmani̇ye, et al.
Archiv der Pharmazie (2021) Vol. 355, Iss. 3
Closed Access | Times Cited: 10
Selected Class of Enamides Bearing Nitro Functionality as Dual-Acting with Highly Selective Monoamine Oxidase-B and BACE1 Inhibitors
Anusree Venkidath, Jong‐Min Oh, Sanal Dev, et al.
Molecules (2021) Vol. 26, Iss. 19, pp. 6004-6004
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top